| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 43 | 2020 | 1111 | 3.690 |
Why?
|
| Postmenopause | 67 | 2024 | 424 | 3.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 29 | 2023 | 1437 | 2.890 |
Why?
|
| Breast Neoplasms | 35 | 2023 | 762 | 2.460 |
Why?
|
| Life Style | 23 | 2023 | 393 | 2.430 |
Why?
|
| Diet | 36 | 2023 | 383 | 2.420 |
Why?
|
| Health Promotion | 15 | 2019 | 242 | 2.290 |
Why?
|
| Weight Loss | 23 | 2020 | 410 | 2.200 |
Why?
|
| Women's Health | 35 | 2024 | 230 | 1.950 |
Why?
|
| Middle Aged | 137 | 2024 | 11851 | 1.810 |
Why?
|
| Feeding Behavior | 18 | 2024 | 154 | 1.740 |
Why?
|
| Female | 167 | 2024 | 19945 | 1.710 |
Why?
|
| Overweight | 17 | 2019 | 252 | 1.700 |
Why?
|
| Aged | 128 | 2024 | 10263 | 1.690 |
Why?
|
| Dietary Supplements | 16 | 2020 | 188 | 1.600 |
Why?
|
| Neoplasms | 16 | 2023 | 754 | 1.540 |
Why?
|
| Humans | 190 | 2024 | 32282 | 1.520 |
Why?
|
| Soybean Proteins | 9 | 2015 | 101 | 1.510 |
Why?
|
| Body Mass Index | 39 | 2020 | 863 | 1.400 |
Why?
|
| Rural Population | 10 | 2022 | 216 | 1.350 |
Why?
|
| Prediabetic State | 7 | 2019 | 76 | 1.350 |
Why?
|
| Risk Factors | 68 | 2024 | 3934 | 1.250 |
Why?
|
| Exercise | 18 | 2024 | 603 | 1.160 |
Why?
|
| Calcium, Dietary | 7 | 2018 | 21 | 1.070 |
Why?
|
| Weight Gain | 7 | 2017 | 104 | 1.000 |
Why?
|
| Cardiovascular Diseases | 16 | 2020 | 1158 | 0.990 |
Why?
|
| Nutrition Policy | 7 | 2016 | 31 | 0.970 |
Why?
|
| Hot Flashes | 6 | 2017 | 49 | 0.970 |
Why?
|
| Male | 70 | 2024 | 19441 | 0.940 |
Why?
|
| African Americans | 22 | 2021 | 1335 | 0.900 |
Why?
|
| United States | 47 | 2024 | 4072 | 0.860 |
Why?
|
| Food Supply | 4 | 2023 | 64 | 0.810 |
Why?
|
| Follow-Up Studies | 31 | 2020 | 2240 | 0.790 |
Why?
|
| Diet, Fat-Restricted | 10 | 2017 | 28 | 0.770 |
Why?
|
| Proportional Hazards Models | 28 | 2020 | 773 | 0.750 |
Why?
|
| Community-Based Participatory Research | 3 | 2019 | 114 | 0.740 |
Why?
|
| Dietary Fats | 9 | 2017 | 99 | 0.740 |
Why?
|
| Health Behavior | 14 | 2024 | 211 | 0.740 |
Why?
|
| Aged, 80 and over | 29 | 2024 | 3900 | 0.720 |
Why?
|
| Prostatic Neoplasms | 6 | 2023 | 489 | 0.710 |
Why?
|
| European Continental Ancestry Group | 18 | 2019 | 1076 | 0.710 |
Why?
|
| Adult | 34 | 2024 | 9259 | 0.710 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 31 | 0.660 |
Why?
|
| Prospective Studies | 31 | 2024 | 2316 | 0.630 |
Why?
|
| Dietary Proteins | 4 | 2015 | 63 | 0.630 |
Why?
|
| Micronutrients | 2 | 2017 | 20 | 0.620 |
Why?
|
| Insulin Resistance | 8 | 2020 | 458 | 0.610 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 1479 | 0.590 |
Why?
|
| Vitamin D | 8 | 2018 | 186 | 0.590 |
Why?
|
| Energy Intake | 10 | 2023 | 122 | 0.590 |
Why?
|
| Blood Glucose | 12 | 2020 | 484 | 0.560 |
Why?
|
| Incidence | 27 | 2024 | 1241 | 0.560 |
Why?
|
| Health Education | 4 | 2017 | 149 | 0.560 |
Why?
|
| Body Composition | 6 | 2019 | 327 | 0.550 |
Why?
|
| Geriatric Assessment | 8 | 2016 | 335 | 0.550 |
Why?
|
| Estrogens | 5 | 2020 | 194 | 0.510 |
Why?
|
| Indians, North American | 9 | 2009 | 75 | 0.510 |
Why?
|
| Food Preferences | 2 | 2008 | 34 | 0.510 |
Why?
|
| Rural Health | 4 | 2007 | 22 | 0.500 |
Why?
|
| Food, Fortified | 1 | 2016 | 4 | 0.500 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2007 | 16 | 0.500 |
Why?
|
| Motor Activity | 9 | 2015 | 332 | 0.480 |
Why?
|
| North Carolina | 17 | 2016 | 1300 | 0.480 |
Why?
|
| Hispanic Americans | 7 | 2019 | 772 | 0.470 |
Why?
|
| Diet, Reducing | 8 | 2015 | 85 | 0.460 |
Why?
|
| Blood Pressure | 3 | 2018 | 861 | 0.440 |
Why?
|
| Abdominal Fat | 1 | 2015 | 39 | 0.430 |
Why?
|
| Chronic Disease | 6 | 2019 | 413 | 0.430 |
Why?
|
| Isoflavones | 4 | 2003 | 103 | 0.420 |
Why?
|
| Cohort Studies | 21 | 2019 | 1840 | 0.420 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 109 | 0.420 |
Why?
|
| Body Weight | 6 | 2019 | 323 | 0.420 |
Why?
|
| Muscle Strength | 1 | 2015 | 135 | 0.410 |
Why?
|
| Patient Compliance | 10 | 2015 | 205 | 0.410 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2014 | 85 | 0.410 |
Why?
|
| Atherosclerosis | 5 | 2023 | 820 | 0.410 |
Why?
|
| Leptin | 7 | 2014 | 61 | 0.400 |
Why?
|
| Cyclohexanols | 1 | 2013 | 22 | 0.400 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 20 | 0.400 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2013 | 41 | 0.400 |
Why?
|
| Waist-Hip Ratio | 7 | 2016 | 32 | 0.400 |
Why?
|
| Risk Assessment | 10 | 2024 | 1425 | 0.370 |
Why?
|
| Food | 2 | 2011 | 42 | 0.370 |
Why?
|
| Insulin | 7 | 2019 | 359 | 0.360 |
Why?
|
| Diet Surveys | 7 | 2018 | 48 | 0.360 |
Why?
|
| Social Marketing | 1 | 2012 | 14 | 0.360 |
Why?
|
| Cholecalciferol | 4 | 2012 | 25 | 0.360 |
Why?
|
| Schools, Medical | 1 | 2012 | 43 | 0.350 |
Why?
|
| Nutrition Assessment | 6 | 2013 | 48 | 0.350 |
Why?
|
| Nutritional Status | 3 | 2023 | 73 | 0.340 |
Why?
|
| Lipids | 4 | 2017 | 253 | 0.330 |
Why?
|
| Patient Education as Topic | 7 | 2014 | 245 | 0.330 |
Why?
|
| Soybeans | 3 | 2014 | 42 | 0.330 |
Why?
|
| Nutritional Requirements | 2 | 2008 | 15 | 0.330 |
Why?
|
| Health Status Disparities | 1 | 2012 | 128 | 0.320 |
Why?
|
| Adiponectin | 4 | 2014 | 94 | 0.320 |
Why?
|
| Widowhood | 2 | 2000 | 2 | 0.320 |
Why?
|
| Colorectal Neoplasms | 5 | 2015 | 219 | 0.320 |
Why?
|
| Self Care | 3 | 2009 | 97 | 0.320 |
Why?
|
| Pilot Projects | 4 | 2023 | 553 | 0.320 |
Why?
|
| Ethnic Groups | 7 | 2018 | 450 | 0.320 |
Why?
|
| Breast | 3 | 2020 | 63 | 0.320 |
Why?
|
| Quality of Life | 7 | 2016 | 964 | 0.320 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 390 | 0.310 |
Why?
|
| Adiposity | 6 | 2016 | 190 | 0.310 |
Why?
|
| Inflammation | 4 | 2016 | 506 | 0.310 |
Why?
|
| Vitamins | 4 | 2018 | 71 | 0.310 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2014 | 42 | 0.300 |
Why?
|
| Parents | 4 | 2024 | 151 | 0.300 |
Why?
|
| Sodium, Dietary | 2 | 2009 | 22 | 0.300 |
Why?
|
| Genome-Wide Association Study | 5 | 2021 | 543 | 0.300 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2016 | 216 | 0.290 |
Why?
|
| Case-Control Studies | 13 | 2016 | 854 | 0.290 |
Why?
|
| Beverages | 1 | 2008 | 17 | 0.290 |
Why?
|
| Longitudinal Studies | 10 | 2016 | 757 | 0.280 |
Why?
|
| Receptors, Estrogen | 4 | 2020 | 104 | 0.280 |
Why?
|
| Patient Preference | 1 | 2008 | 48 | 0.280 |
Why?
|
| Risk | 9 | 2019 | 305 | 0.280 |
Why?
|
| Fatty Acids | 5 | 2019 | 100 | 0.280 |
Why?
|
| Endometrial Neoplasms | 3 | 2018 | 49 | 0.280 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 50 | 0.280 |
Why?
|
| Coronary Disease | 5 | 2014 | 226 | 0.280 |
Why?
|
| Prognosis | 9 | 2018 | 1534 | 0.280 |
Why?
|
| Double-Blind Method | 9 | 2017 | 565 | 0.270 |
Why?
|
| Health Status | 8 | 2023 | 355 | 0.270 |
Why?
|
| Treatment Outcome | 13 | 2017 | 3416 | 0.270 |
Why?
|
| Feasibility Studies | 2 | 2022 | 308 | 0.270 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 168 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2012 | 316 | 0.270 |
Why?
|
| Community Health Services | 3 | 2013 | 47 | 0.270 |
Why?
|
| Sweating | 3 | 2017 | 16 | 0.260 |
Why?
|
| Aspirin | 3 | 2018 | 59 | 0.260 |
Why?
|
| Socioeconomic Factors | 8 | 2017 | 388 | 0.260 |
Why?
|
| Logistic Models | 8 | 2017 | 743 | 0.250 |
Why?
|
| Child, Preschool | 5 | 2024 | 1233 | 0.250 |
Why?
|
| African Continental Ancestry Group | 2 | 2021 | 338 | 0.240 |
Why?
|
| Adipose Tissue | 3 | 2014 | 320 | 0.240 |
Why?
|
| Educational Status | 6 | 2018 | 167 | 0.240 |
Why?
|
| Mortality | 3 | 2016 | 122 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 1050 | 0.240 |
Why?
|
| Cognition Disorders | 3 | 2016 | 349 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 66 | 0.240 |
Why?
|
| Folic Acid | 2 | 2016 | 11 | 0.240 |
Why?
|
| Heart Conduction System | 4 | 2014 | 76 | 0.230 |
Why?
|
| Stress, Psychological | 2 | 2024 | 217 | 0.230 |
Why?
|
| Mental Health | 2 | 2024 | 111 | 0.230 |
Why?
|
| Ovarian Neoplasms | 2 | 2018 | 84 | 0.230 |
Why?
|
| Nutrition Surveys | 4 | 2019 | 144 | 0.230 |
Why?
|
| Dietary Fiber | 4 | 2015 | 20 | 0.230 |
Why?
|
| Health Surveys | 4 | 2020 | 175 | 0.220 |
Why?
|
| Phytotherapy | 2 | 2017 | 36 | 0.220 |
Why?
|
| Time Factors | 7 | 2018 | 2205 | 0.220 |
Why?
|
| Energy Metabolism | 3 | 2019 | 153 | 0.220 |
Why?
|
| Trans Fatty Acids | 3 | 2017 | 10 | 0.220 |
Why?
|
| Stroke | 4 | 2024 | 691 | 0.210 |
Why?
|
| Vitamin D Deficiency | 2 | 2018 | 87 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Fathers | 1 | 2024 | 12 | 0.210 |
Why?
|
| Metformin | 2 | 2015 | 25 | 0.210 |
Why?
|
| Radon | 1 | 2024 | 1 | 0.210 |
Why?
|
| Osteoarthritis, Hip | 1 | 2024 | 17 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Electrocardiography | 3 | 2014 | 623 | 0.210 |
Why?
|
| Progesterone | 2 | 2023 | 78 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 312 | 0.200 |
Why?
|
| Fabaceae | 1 | 2023 | 2 | 0.200 |
Why?
|
| Age Factors | 8 | 2018 | 1179 | 0.200 |
Why?
|
| Comorbidity | 4 | 2019 | 565 | 0.200 |
Why?
|
| Mothers | 1 | 2024 | 74 | 0.200 |
Why?
|
| Osteoarthritis, Knee | 1 | 2024 | 69 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2024 | 65 | 0.200 |
Why?
|
| Survivors | 2 | 2016 | 173 | 0.200 |
Why?
|
| Body Height | 2 | 2021 | 34 | 0.200 |
Why?
|
| Walking | 2 | 2015 | 200 | 0.200 |
Why?
|
| Vasomotor System | 2 | 2014 | 25 | 0.200 |
Why?
|
| Hypertension | 5 | 2018 | 979 | 0.190 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2024 | 95 | 0.190 |
Why?
|
| Lycopersicon esculentum | 2 | 2014 | 6 | 0.190 |
Why?
|
| Bundle-Branch Block | 2 | 2013 | 22 | 0.190 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 186 | 0.190 |
Why?
|
| Eating | 3 | 2020 | 77 | 0.180 |
Why?
|
| Bone Density Conservation Agents | 2 | 2012 | 23 | 0.180 |
Why?
|
| Vegetables | 5 | 2024 | 39 | 0.180 |
Why?
|
| Physical Fitness | 4 | 2014 | 120 | 0.180 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 183 | 0.170 |
Why?
|
| Students, Medical | 2 | 2013 | 126 | 0.170 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2013 | 157 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2017 | 477 | 0.170 |
Why?
|
| Minerals | 1 | 2000 | 14 | 0.160 |
Why?
|
| Anticarcinogenic Agents | 2 | 2014 | 26 | 0.160 |
Why?
|
| Receptor, erbB-2 | 2 | 2011 | 63 | 0.160 |
Why?
|
| Nutritional Sciences | 1 | 2000 | 6 | 0.160 |
Why?
|
| Selenium | 1 | 2020 | 3 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 7 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 117 | 0.160 |
Why?
|
| Urban Population | 3 | 2019 | 91 | 0.160 |
Why?
|
| Alcohol Drinking | 5 | 2015 | 255 | 0.160 |
Why?
|
| Regression Analysis | 6 | 2015 | 273 | 0.160 |
Why?
|
| Hip Fractures | 3 | 2014 | 26 | 0.160 |
Why?
|
| Child | 4 | 2023 | 2435 | 0.160 |
Why?
|
| Linear Models | 5 | 2014 | 425 | 0.160 |
Why?
|
| Obesity, Abdominal | 3 | 2014 | 24 | 0.160 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2017 | 9 | 0.150 |
Why?
|
| Independent Living | 1 | 2020 | 90 | 0.150 |
Why?
|
| Prevalence | 3 | 2019 | 955 | 0.150 |
Why?
|
| Parity | 2 | 2017 | 19 | 0.150 |
Why?
|
| Mitochondria, Muscle | 1 | 2019 | 18 | 0.150 |
Why?
|
| Menopause | 3 | 2015 | 109 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2010 | 31 | 0.150 |
Why?
|
| Birth Weight | 1 | 2019 | 46 | 0.150 |
Why?
|
| Metabolomics | 1 | 2020 | 63 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 131 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2014 | 22 | 0.150 |
Why?
|
| Betaine | 1 | 2019 | 2 | 0.150 |
Why?
|
| Bacteria | 1 | 2019 | 54 | 0.150 |
Why?
|
| Estradiol | 3 | 2023 | 139 | 0.150 |
Why?
|
| Aging | 5 | 2016 | 942 | 0.150 |
Why?
|
| Choline | 1 | 2019 | 18 | 0.150 |
Why?
|
| Breast Feeding | 2 | 2017 | 47 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 555 | 0.140 |
Why?
|
| Fruit | 4 | 2024 | 51 | 0.140 |
Why?
|
| Troponin T | 1 | 2019 | 92 | 0.140 |
Why?
|
| Adolescent | 5 | 2019 | 3519 | 0.140 |
Why?
|
| Pregnancy | 3 | 2017 | 961 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2019 | 70 | 0.140 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 10 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 381 | 0.140 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 651 | 0.140 |
Why?
|
| Waist Circumference | 5 | 2016 | 91 | 0.130 |
Why?
|
| Cognition | 2 | 2015 | 547 | 0.130 |
Why?
|
| Diet Records | 7 | 2017 | 31 | 0.130 |
Why?
|
| Disability Evaluation | 2 | 2016 | 242 | 0.130 |
Why?
|
| Patient Participation | 3 | 2013 | 90 | 0.130 |
Why?
|
| Interviews as Topic | 3 | 2007 | 194 | 0.130 |
Why?
|
| Young Adult | 6 | 2019 | 2649 | 0.130 |
Why?
|
| Awareness | 2 | 2017 | 23 | 0.130 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Dietary Carbohydrates | 1 | 2017 | 21 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 33 | 0.130 |
Why?
|
| Odds Ratio | 6 | 2017 | 456 | 0.130 |
Why?
|
| Mental Recall | 5 | 2013 | 47 | 0.130 |
Why?
|
| Ethics, Research | 1 | 2017 | 25 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 220 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 84 | 0.130 |
Why?
|
| Social Class | 2 | 2007 | 90 | 0.130 |
Why?
|
| Social Support | 2 | 2013 | 180 | 0.120 |
Why?
|
| Caffeine | 1 | 2016 | 28 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 757 | 0.120 |
Why?
|
| Prejudice | 2 | 2013 | 45 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2017 | 61 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 294 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2016 | 49 | 0.120 |
Why?
|
| Behavior Therapy | 2 | 2014 | 102 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2016 | 69 | 0.120 |
Why?
|
| Phytanic Acid | 2 | 2006 | 5 | 0.120 |
Why?
|
| Dairy Products | 2 | 2013 | 13 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2017 | 142 | 0.120 |
Why?
|
| Frail Elderly | 1 | 2016 | 69 | 0.110 |
Why?
|
| Tennessee | 1 | 2015 | 98 | 0.110 |
Why?
|
| Veterans | 1 | 2016 | 64 | 0.110 |
Why?
|
| Antioxidants | 2 | 2017 | 122 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 167 | 0.110 |
Why?
|
| Recreation | 2 | 2016 | 12 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 137 | 0.110 |
Why?
|
| Foods, Specialized | 1 | 2015 | 1 | 0.110 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 520 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 363 | 0.110 |
Why?
|
| Sweetening Agents | 1 | 2014 | 8 | 0.110 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 6 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2013 | 9 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2015 | 54 | 0.110 |
Why?
|
| Community Health Centers | 1 | 2014 | 12 | 0.110 |
Why?
|
| Hand Strength | 1 | 2015 | 98 | 0.110 |
Why?
|
| Disease Progression | 2 | 2014 | 591 | 0.110 |
Why?
|
| Spinal Fractures | 1 | 2014 | 37 | 0.110 |
Why?
|
| Animals | 7 | 2023 | 8199 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2015 | 192 | 0.110 |
Why?
|
| Patient Selection | 3 | 2010 | 272 | 0.110 |
Why?
|
| Ibuprofen | 1 | 2014 | 3 | 0.110 |
Why?
|
| Naproxen | 1 | 2014 | 7 | 0.100 |
Why?
|
| Smoking | 3 | 2015 | 505 | 0.100 |
Why?
|
| Models, Statistical | 2 | 2014 | 187 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 410 | 0.100 |
Why?
|
| Testosterone | 2 | 2011 | 48 | 0.100 |
Why?
|
| Resistin | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 61 | 0.100 |
Why?
|
| Caloric Restriction | 1 | 2015 | 92 | 0.100 |
Why?
|
| Family Characteristics | 2 | 2024 | 32 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 285 | 0.100 |
Why?
|
| Milk | 1 | 2013 | 13 | 0.100 |
Why?
|
| Bone Density | 1 | 2014 | 169 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 25 | 0.100 |
Why?
|
| Infant | 1 | 2016 | 1010 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 100 | 0.100 |
Why?
|
| Social Desirability | 1 | 2013 | 12 | 0.100 |
Why?
|
| C-Reactive Protein | 4 | 2016 | 227 | 0.100 |
Why?
|
| Body Image | 1 | 2013 | 19 | 0.100 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2013 | 112 | 0.100 |
Why?
|
| Ubiquinone | 1 | 2013 | 7 | 0.100 |
Why?
|
| Mammography | 4 | 2020 | 41 | 0.100 |
Why?
|
| Social Behavior | 1 | 2013 | 69 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 94 | 0.100 |
Why?
|
| Social Welfare | 1 | 2012 | 4 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2013 | 193 | 0.100 |
Why?
|
| Calcium Carbonate | 1 | 2012 | 8 | 0.100 |
Why?
|
| Fatigue | 1 | 2013 | 76 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 541 | 0.090 |
Why?
|
| Iron, Dietary | 1 | 2012 | 8 | 0.090 |
Why?
|
| Adipokines | 1 | 2012 | 11 | 0.090 |
Why?
|
| Ferritins | 1 | 2012 | 38 | 0.090 |
Why?
|
| Hemochromatosis | 1 | 2012 | 44 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 45 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2014 | 208 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 293 | 0.090 |
Why?
|
| Family | 1 | 2012 | 112 | 0.090 |
Why?
|
| South Africa | 2 | 2023 | 14 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 883 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 28 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2011 | 23 | 0.090 |
Why?
|
| Reproductive History | 1 | 2011 | 5 | 0.080 |
Why?
|
| Respiratory Aspiration | 1 | 2011 | 24 | 0.080 |
Why?
|
| Resistance Training | 1 | 2011 | 58 | 0.080 |
Why?
|
| Body Size | 1 | 2011 | 35 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 1 | 2011 | 58 | 0.080 |
Why?
|
| Contraceptives, Oral | 1 | 2011 | 26 | 0.080 |
Why?
|
| Deglutition | 1 | 2011 | 30 | 0.080 |
Why?
|
| Depression | 1 | 2014 | 420 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2012 | 75 | 0.080 |
Why?
|
| Communications Media | 1 | 2010 | 4 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2012 | 243 | 0.080 |
Why?
|
| Heart Failure | 2 | 2018 | 728 | 0.080 |
Why?
|
| Minority Groups | 1 | 2011 | 81 | 0.080 |
Why?
|
| Body Weights and Measures | 1 | 2010 | 23 | 0.080 |
Why?
|
| Texas | 3 | 2015 | 40 | 0.080 |
Why?
|
| Arthralgia | 1 | 2010 | 29 | 0.080 |
Why?
|
| Amplifiers, Electronic | 1 | 1990 | 3 | 0.080 |
Why?
|
| Blood Pressure Monitors | 1 | 1990 | 4 | 0.080 |
Why?
|
| Acoustics | 1 | 1990 | 4 | 0.080 |
Why?
|
| Anthropometry | 4 | 2016 | 89 | 0.080 |
Why?
|
| Erythrocytes | 2 | 2024 | 41 | 0.080 |
Why?
|
| Curriculum | 1 | 2012 | 203 | 0.080 |
Why?
|
| Genetic Loci | 3 | 2017 | 143 | 0.080 |
Why?
|
| Continental Population Groups | 3 | 2018 | 228 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 166 | 0.080 |
Why?
|
| Focus Groups | 2 | 2011 | 123 | 0.080 |
Why?
|
| Macaca fascicularis | 2 | 2023 | 542 | 0.080 |
Why?
|
| Cholesterol, HDL | 3 | 2014 | 181 | 0.080 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2024 | 43 | 0.080 |
Why?
|
| Premenopause | 2 | 2007 | 53 | 0.070 |
Why?
|
| Reference Values | 4 | 2017 | 238 | 0.070 |
Why?
|
| Haplorhini | 2 | 2019 | 75 | 0.070 |
Why?
|
| Cause of Death | 3 | 2016 | 236 | 0.070 |
Why?
|
| Calcium Compounds | 1 | 2008 | 9 | 0.070 |
Why?
|
| Fasting | 2 | 2020 | 88 | 0.070 |
Why?
|
| Interleukin-6 | 3 | 2014 | 224 | 0.070 |
Why?
|
| Dementia | 1 | 2011 | 246 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 595 | 0.070 |
Why?
|
| Coffee | 1 | 2007 | 8 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 113 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 187 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2007 | 76 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2007 | 48 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 46 | 0.060 |
Why?
|
| Kidney | 1 | 2011 | 521 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 126 | 0.060 |
Why?
|
| Racemases and Epimerases | 1 | 2006 | 5 | 0.060 |
Why?
|
| Poverty | 1 | 2007 | 105 | 0.060 |
Why?
|
| Research Design | 2 | 2023 | 314 | 0.060 |
Why?
|
| Dietary Sucrose | 1 | 2006 | 10 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 471 | 0.060 |
Why?
|
| Cholesterol | 3 | 2014 | 262 | 0.060 |
Why?
|
| Taste | 1 | 2005 | 17 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 128 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 853 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 276 | 0.050 |
Why?
|
| Triglycerides | 3 | 2014 | 235 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2016 | 215 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 167 | 0.050 |
Why?
|
| Parent-Child Relations | 1 | 2024 | 45 | 0.050 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2024 | 36 | 0.050 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2024 | 68 | 0.050 |
Why?
|
| Family Relations | 1 | 2023 | 19 | 0.050 |
Why?
|
| Perception | 1 | 2024 | 99 | 0.050 |
Why?
|
| Menstruation Disturbances | 1 | 2023 | 5 | 0.050 |
Why?
|
| Residence Characteristics | 2 | 2017 | 178 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3626 | 0.050 |
Why?
|
| Climacteric | 1 | 2003 | 6 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 191 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 79 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2023 | 32 | 0.050 |
Why?
|
| Cholesterol, LDL | 3 | 2014 | 170 | 0.050 |
Why?
|
| Survival Rate | 2 | 2018 | 893 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 94 | 0.050 |
Why?
|
| Thinness | 2 | 2014 | 32 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 292 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2015 | 302 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 655 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2001 | 29 | 0.040 |
Why?
|
| Primary Prevention | 3 | 2006 | 55 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2012 | 106 | 0.040 |
Why?
|
| Anxiety | 1 | 2023 | 190 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 22 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 26 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2011 | 65 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2001 | 99 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 82 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2000 | 15 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 33 | 0.040 |
Why?
|
| Purines | 1 | 2020 | 21 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 40 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 9 | 0.040 |
Why?
|
| Caseins | 1 | 1999 | 21 | 0.040 |
Why?
|
| Uterine Prolapse | 1 | 1999 | 21 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 821 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 146 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 77 | 0.040 |
Why?
|
| Developing Countries | 1 | 2019 | 57 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 67 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 1999 | 68 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2011 | 15 | 0.040 |
Why?
|
| Psychosocial Deprivation | 1 | 1998 | 2 | 0.040 |
Why?
|
| Primates | 1 | 2019 | 128 | 0.040 |
Why?
|
| Food Services | 1 | 1998 | 19 | 0.030 |
Why?
|
| Culture | 2 | 2013 | 34 | 0.030 |
Why?
|
| Systole | 1 | 2018 | 94 | 0.030 |
Why?
|
| Gardening | 1 | 2017 | 2 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 55 | 0.030 |
Why?
|
| Environment | 1 | 2017 | 47 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2017 | 10 | 0.030 |
Why?
|
| Intellectual Property | 1 | 2017 | 1 | 0.030 |
Why?
|
| Dietetics | 1 | 2017 | 4 | 0.030 |
Why?
|
| Patients | 1 | 2017 | 46 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 32 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2017 | 60 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 24 | 0.030 |
Why?
|
| Powders | 1 | 2017 | 8 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 171 | 0.030 |
Why?
|
| Ideal Body Weight | 1 | 2016 | 6 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1997 | 147 | 0.030 |
Why?
|
| Health Personnel | 1 | 2017 | 112 | 0.030 |
Why?
|
| Interleukins | 1 | 2016 | 17 | 0.030 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 3 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 167 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 110 | 0.030 |
Why?
|
| Forecasting | 1 | 2006 | 144 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2018 | 243 | 0.030 |
Why?
|
| Women | 1 | 2015 | 12 | 0.030 |
Why?
|
| Plasma | 1 | 2015 | 14 | 0.030 |
Why?
|
| C-Peptide | 1 | 2014 | 31 | 0.030 |
Why?
|
| Calcifediol | 1 | 2014 | 10 | 0.030 |
Why?
|
| Brugada Syndrome | 1 | 2014 | 18 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 622 | 0.030 |
Why?
|
| United States Department of Agriculture | 1 | 2013 | 3 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2014 | 74 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 466 | 0.030 |
Why?
|
| Food Handling | 1 | 2013 | 7 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 47 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 150 | 0.030 |
Why?
|
| Semantic Differential | 1 | 2013 | 5 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 120 | 0.030 |
Why?
|
| Nitrogen | 1 | 2013 | 10 | 0.020 |
Why?
|
| Calibration | 1 | 2013 | 24 | 0.020 |
Why?
|
| Decision Trees | 1 | 2013 | 30 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 150 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 324 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 368 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2012 | 13 | 0.020 |
Why?
|
| Urinary Calculi | 1 | 2012 | 7 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 211 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 51 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 181 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 93 | 0.020 |
Why?
|
| Motivation | 1 | 2013 | 120 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 200 | 0.020 |
Why?
|
| Homozygote | 1 | 2012 | 52 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2012 | 13 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 63 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2013 | 148 | 0.020 |
Why?
|
| Telemedicine | 1 | 2014 | 122 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 122 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2013 | 179 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2012 | 21 | 0.020 |
Why?
|
| Vitamin A | 1 | 2012 | 21 | 0.020 |
Why?
|
| Restaurants | 1 | 2011 | 9 | 0.020 |
Why?
|
| Human Growth Hormone | 1 | 2011 | 4 | 0.020 |
Why?
|
| Fructosamine | 1 | 2011 | 12 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 2011 | 11 | 0.020 |
Why?
|
| Group Processes | 1 | 2011 | 12 | 0.020 |
Why?
|
| Social Environment | 1 | 2011 | 74 | 0.020 |
Why?
|
| Illinois | 1 | 2011 | 10 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 32 | 0.020 |
Why?
|
| Viscosity | 1 | 2011 | 25 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 8 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 179 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2013 | 255 | 0.020 |
Why?
|
| Menarche | 1 | 2011 | 4 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 22 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 73 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 16 | 0.020 |
Why?
|
| Renal Plasma Flow | 1 | 2011 | 1 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 25 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2010 | 98 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 16 | 0.020 |
Why?
|
| Crystallography | 1 | 1990 | 2 | 0.020 |
Why?
|
| Microcomputers | 1 | 1990 | 6 | 0.020 |
Why?
|
| Joint Diseases | 1 | 2010 | 31 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 77 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 70 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 363 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 475 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 287 | 0.020 |
Why?
|
| Osteoarthritis | 1 | 2010 | 73 | 0.020 |
Why?
|
| Mass Screening | 1 | 2012 | 256 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 497 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2012 | 232 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 1990 | 106 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 536 | 0.020 |
Why?
|
| Heart Rate | 1 | 1990 | 362 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 22 | 0.020 |
Why?
|
| Carotid Artery, Internal | 1 | 2007 | 33 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 55 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2006 | 17 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2006 | 50 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2006 | 40 | 0.010 |
Why?
|
| Adenoma | 1 | 2006 | 35 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 174 | 0.010 |
Why?
|
| Meat | 1 | 2005 | 16 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 2007 | 250 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 179 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 22 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 408 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 1999 | 25 | 0.010 |
Why?
|
| Decision Making | 1 | 2000 | 189 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1997 | 126 | 0.010 |
Why?
|
| Software | 1 | 1997 | 124 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1997 | 251 | 0.010 |
Why?
|